Sustainability Challenges in Peptide Synthesis and Purification: From R&D to Production
GlaxoSmithKline (Ireland) · AstraZeneca (United Kingdom) · +8 more institutions
Abstract
In recent years, there has been a growing interest in therapeutic peptides within the pharmaceutical industry with more than 50 peptide drugs on the market, approximately 170 in clinical trials, and >200 in preclinical development. However, the current state of the art in peptide synthesis involves primarily legacy technologies with use of large amounts of highly hazardous reagents and solvents and little focus on green chemistry and engineering. In 2016, the ACS Green Chemistry Institute Pharmaceutical Roundtable identified development of greener processes for peptide API as a critical unmet need, and as a result, a new Roundtable team formed to address this important area. The initial focus of this new team…
Citation impact
- FWCI
- 16.66
- Percentile
- 100%
- References
- 153
Authors
8- AIAlbert Isidro‐LlobetCorresponding
GlaxoSmithKline (Ireland)
- MNMartin N. KenworthyCorresponding
AstraZeneca (United Kingdom), AstraZeneca (Singapore), AstraZeneca (Poland)
- SMSubha MukherjeeCorresponding
Bristol-Myers Squibb (United States), Université Bourgogne Franche-Comté
- MEMichael E. KopachCorresponding
Eli Lilly (United States)
- KWKatarzyna WegnerCorresponding
Topics & keywords
- Sustainability
- Pharmaceutical industry
- Business
- Production (economics)
- Engineering ethics
- Biotechnology
- Engineering
- Economics
- Industry, innovation and infrastructure